Holen Sie sich die Stockscreener-App
24.65
0.74%
0.18
Pacira Biosciences Inc Aktie (PCRX) Neueste Nachrichten
(PCRX) Investment Analysis and Advice - news.stocktradersdaily.com
Pacira (PCRX) Announces New $300M Share Repurchase Plan | PCRX Stock News - GuruFocus
Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders - The Manila Times
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Shareholders to Inquire about Securities Investigation - markets.businessinsider.com
Pacira Biosciences IncAuthorizes $300 Million Share Repurchase Program - marketscreener.com
Pacira Biosciences Approves $300M Share Buyback - MarketWatch
Pacira BioSciences initiates $300 million buyback plan - Investing.com
Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders | PCRX Stock News - GuruFocus
Pacira BioSciences Announces $300M Share Buyback and '5x30' Growth Plan: Double-Digit Revenue Growth Targeted - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRA) And Encourages Shareholders to Connect - markets.businessinsider.com
Is Pacira BioSciences, Inc. (PCRX) the Best Pharma Stock to Buy for Long Term Growth? - Yahoo Finance
10 Best Pharma Stocks to Buy for Long Term Growth - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRA) And Encourages Shareholders to Reach Out - markets.businessinsider.com
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listin - GuruFocus
Raymond James Financial Inc. Acquires Shares of 10,099 Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule - MarketScreener
Pacira BioSciences (PCRX) Grants Inducement Awards to New Employ - GuruFocus
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Pacira's Latest Move: 66,500 Shares in Stock Awards Signal Aggressive Talent Push - Stock Titan
Sei Investments Co. Sells 7,231 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Stockholders to Inquire about Securities Investigation - markets.businessinsider.com
Taking the lead: Pacira BioSciences Inc (PCRX) - Sete News
The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb - Yahoo Finance
Vanguard Group Inc. Decreases Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Pacira Biosciences' SWOT analysis: stock outlook amid litigation settlement - Investing.com Australia
Pacira Biosciences' SWOT analysis: stock outlook amid litigation settlement By Investing.com - Investing.com South Africa
Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More - Yahoo Finance
Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN Act - Seeking Alpha
Pacira (PCRX) Surges 14.7%: Is This an Indication of Further Gains? - Yahoo Finance
Pacira Biosciences’ SWOT analysis: stock outlook amid litigation settlement By Investing.com - Investing.com UK
Corebridge Financial Inc. Trims Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives $27.22 Average Target Price from Analysts - The AM Reporter
Pacira BioSciences (NASDAQ:PCRX) Shares Gap Up After Analyst Upgrade - Defense World
Pacira Reaches IP Deal Allowing Generic Painkiller In 2030 - Law360
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Investors to Learn More About the Investigation - markets.businessinsider.com
PCRX Stock Soars on Exparel Patent Settlement With Generic Players - Zacks Investment Research
Pacira Biosciences Stock Rises On Patent Litigation Settlement: Retail Sentiment Soars - MSN
Forecasting The Future: 8 Analyst Projections For Pacira BioSciences - Benzinga
Pacira Biosciences Resolves Patent Disputes, Shares Jump Over 21% - Finimize
RBC Raises Price Target on Pacira Biosciences to $26 From $22, Keeps Sector Perform Rating - MarketScreener
Truist Raises Price Target on Pacira Biosciences to $28 From $25, Keeps Hold Rating - MarketScreener
Pacira Biosciences Settles Patent Litigations Over Local Analgesic; Shares Rise Pre-bell - MarketScreener
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Purchased by American Century Companies Inc. - Defense World
Pacira BioSciences (PCRX) Shares Spike 15% After Patent Settleme - GuruFocus
Pacira surges on patent settlement with Fresenius - MSN
Pacira Pharmaceuticals Settles Patent Litigation with Fresenius - TipRanks
Pacira stock surges on patent settlement (PCRX:NASDAQ) - Seeking Alpha
Pacira Biosciences Announces Settlement Of U.S. Patent Litigation For Exparel - MarketScreener
Pacira BioSciences stock surges on patent litigation settlement By Investing.com - Investing.com Canada
Pacira BioSciences stock surges on patent litigation settlement - Investing.com Australia
Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL - GlobeNewswire
Pacira Wins Strategic Patent Deal: EXPAREL Maintains Market Dominance Through 2030 - Stock Titan
Pacira BioSciences, Inc. (NASDAQ:PCRX) Looks Inexpensive But Perhaps Not Attractive Enough - simplywall.st
Arrowstreet Capital Limited Partnership Sells 505,307 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - The AM Reporter
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives $27.22 Consensus Price Target from Analysts - Defense World
Pacira BioSciences, Inc. (PCRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
KLP Kapitalforvaltning AS Makes New $447,000 Investment in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
PCRX Doses First Patient in Phase II PCRX-201 Gene Therapy Study - Nasdaq
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRA) And Encourages Investors to Connect - markets.businessinsider.com
Pacira launches Phase 2 osteoarthritis gene therapy trial - Investing.com
Pacira BioSciences Announces First Patient Dosed in Phase 2 - GlobeNewswire
Pacira Biosciences Announces First Patient Dosed In Phase 2 Study Evaluating Safety And Efficacy Of Pcrx-201 For The Treatment Of Osteoarthritis Of The Knee - MarketScreener
Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and ... - Bluefield Daily Telegraph
0.74%
0.80%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):